Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

The FDA has approved Gamifant as the first-ever treatment for macrophage activation syndrome in Still’s disease for adults ...

Aquestive Therapeutics, Inc. (NASDAQ:AQST) is among the best growth stocks to invest in for the next 5 years. Analysts at H.C ...

The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.

A common drug used for inflammatory skin conditions may hold the key to treating both alcohol addiction and pain sensitivity.

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Emapalumab is approved for both adults and pediatric (newborn and older) patients with MAS in Still disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS.

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.